KR20190038106A - Composition comprising fermented tea extract for Enhancing Skin Barrier - Google Patents

Abstract

Disclosed in the present specification is a composition comprising a fermented tea extract as an active ingredient for strengthening a skin barrier, wherein the expression of at least one selected from the group consisting of S100A7 (NM_002963), IL-36G (NM_019618) and LCE3D (NM_032563), which are genes in skin cells, having expression levels affected by stimuli that weaken the skin barrier, is regulated to a normal level. By using the composition for strengthening the skin barrier, gene expression changed by the stimuli that weaken the skin barrier can return to a normal level to reduce skin cell damage.

Description

[0001] The present invention relates to a composition for enhancing skin barrier comprising a fermented tea extract,

Disclosed herein are compositions for enhancing skin barrier. More specifically, a composition comprising a fermented tea extract that strengthens a skin barrier by significantly changing a biomarker such as a skin cell gene whose expression level is changed by attenuation of a skin barrier as compared with a normal skin cell is disclosed do.

Among the constitutive layers of the skin, the epidermis plays an important role in preventing water evaporation inside the human body. The epidermis is divided into stratum corneum, granular layer, superficial layer, and basal layer in order from the outside. Cells of stratum corneum act like bricks, and interstitial lipids between keratinocytes act like mortar to form skin barrier. In addition, a healthy human keratinocyte has a high concentration of natural moisturizing factor (NMF) to help maintain moisture in the skin. For example, substances such as amino acids are water-soluble, Thereby suppressing drying.

However, as it is nowadays, there is a tendency to adjust the temperature of the air / heating due to the change of environment or life pattern, the stress caused by various stresses and environmental pollution in the social life, frequent washing according to make- Due to various causes such as aging of the skin, the skin becomes dry, the surface becomes rough, the skin becomes loose, the moisture is lost, and the appearance of the skin does not appear, and thus the need for a skin moisturizer increases . Excessive physical and chemical stimuli, ultraviolet rays, stress and nutrient deficiency, which are externally received, can lower the normal functions of the skin and promote elasticity loss, keratinization and wrinkle formation. Especially, . Excessive physical, chemical stimuli, ultraviolet rays, and stress from the outside of the skin lower the normal functions of the skin and promote skin aging phenomenon such as loss of elasticity, keratinization, and wrinkle formation. Especially, .

It is known that IL-36G is a useful biomarker in psoriasis caused by skin barrier weakness (see Non-Patent Document 1). It is also known that S100A7 is an index related to atopic dermatitis and psoriasis due to impairment of skin barrier function (see Non-Patent Document 2). It is also known that LCE3D is an index related to the psoriasis risk gene (see Non-Patent Document 3). Which are incorporated herein by reference in their entirety.

AM D'Erme, " IL-36c (IL-lF9) Is a Biomarker for Psoriasis Skin Lesions ", Journal of Investigative Dermatology, Volume 135, 2015. Son et al, " S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL-6 secretion through IJB / NF-JB signaling ", Experimental Dermatology, John Wiley & Sons A / S, Bergboer et al, " Psoriasis Risk Genes of the Late Corned Envelope-3 Group Are Distinctly Expressed Compared with Genes of Other LCE Groups ", The American Journal of Pathology, Vol. 178, No. 4, April 2011.

Thus, the present inventors have found that a stimulus source that causes skin barrier weakness has a detrimental effect on the skin, and by such influence, affects the expression of a skin cell gene, thereby causing symptoms such as a stimulus source that causes skin barrier weakness.

Therefore, in one aspect, the present invention aims to provide a composition for skin barrier enhancement.

In order to attain the above object, in one aspect, the present invention provides a composition comprising an extract of fermented tea as an active ingredient, wherein S100A7 (NM_002963), a gene in a skin cell to which an expression amount is influenced by a stimulus source causing skin barrier weakness, , IL-36G (NM_019618), and LCE3D (NM_032563) to a normal level.

In one aspect, by using the composition for skin barrier enhancement provided by the present invention, it is possible to reduce the damage of skin cells by returning the amount of gene expression, which is changed by a stimulus source causing skin barrier weakness, to a normal level.

1 shows the cell survival rate by stimulus treatment, wherein ADSP represents Asian dust-storm particles, and PM10 (Particulate matter 10) represents fine dust particles having a particle size of 10 μm And PM 2.5 (Particulate matter 2.5) represent fine dust particles having a particle size of 2.5 μm.
FIG. 2A shows that mRNA expression of IL-36G gene was increased in skin cells stimulated with skin barrier weakness and returned to a normal level by treatment with fermentation tea.
FIG. 2B shows an increase in the mRNA expression level of the LCE3D gene in the skin cells to which the stimulus causing the weakening of the skin barrier was applied, and returned to the normal level by the treatment of the fermentation tea.
FIG. 2C shows that the mRNA expression level of the S100A7 gene was increased in the skin cells stimulated to cause skin barrier weakness, and returned to the normal level by the fermentation tea treatment.
FIG. 3 is a chromatogram of the raw material TIC, the crude chicic acid seeds, and the crude chicic acid standard product as a result of analyzing the fermented tea components through liquid chromatography-mass spectrometry (High Resolution LC-MS).

Hereinafter, the present invention will be described in detail.

In one aspect of the present invention, the skin barrier enhancer composition may include a fermented tea extract as an active ingredient.

As used herein, the term " fermented tea " means a fermented tea, and specifically means a post-fermented tea.

As used herein, the term " post fermentation tea " means a tea fermented and aged using microorganisms under appropriate moisture and temperature conditions.

In one aspect, the post-fermentation tea used herein may be included as a pulverized product of the post-fermentation tea itself, or as a dry pulverized product of a post-fermentation tea, but is not limited thereto.

In one aspect of the present invention, the fermentation car may contain quinic acid.

In the composition for skin barrier strengthening according to an embodiment of the present invention, the tea may be green tea. In another aspect of the present invention, the tea may be a tea fermented with green tea.

In one aspect, the fermentation tea may be fermented and aged.

In one aspect, the fermentation tea may be a fermentation tea obtained by naturally fermenting a tea leaf in which an internal enzyme is inactivated.

In one aspect of the present invention, the fermented tea may be extracted with a specific extraction solvent to form a fermented tea extract.

In one aspect of the present invention, the fermented tea extract may be prepared by extracting a fermented tea with water or an organic solvent. Concretely, the fermentation tea is mixed with water, at least one selected from the group consisting of C ₁ -C ₆ anhydrous or lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane And extracting it with an extraction solvent.

In one aspect, the fermented tea extract may be extracted at room temperature.

In one aspect, the fermented tea extract may be obtained by extracting with the extraction solvent, followed by addition of one or more of filtration, concentration, separation or drying. In particular, the fermented tea extract may be subjected to one or more filtration processes, and in one embodiment, it is subjected to two filtration processes.

In one embodiment, the separation process may include a centrifugation process.

Specifically, the extraction can be carried out in the presence of water, a C ₁ -C ₆ anhydrous or a lower alcohol, a polar solvent comprising acetone and butylene glycol, and a polar solvent including ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane And a low polarity solvent may be used as a solvent.

More specifically, the solvent may be 50-90% ethanol aqueous solution, and may be 60-80% ethanol or 65-75% ethanol aqueous solution. When the solvent is 50-90% aqueous ethanol solution, the active ingredient can be effectively extracted from the fermented tea. In one embodiment, the solvent may be about 70% aqueous ethanol solution.

In one aspect, the extract may be concentrated under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction.

However, the fermented tea extract according to the present invention can be extracted by a conventional method in the art, and is not limited by the above-mentioned method.

In one aspect of the present invention, the composition may comprise from 0.000001 to 30% by weight of fermented tea extract, based on the total weight of the composition. When the content is 0.000001 to 30% by weight, the skin barrier enhancement effect by the fermented tea extract is excellent.

More specifically, 0.0000001 wt% or more, 0.0000005 wt% or more, 0.0000007 wt% or more, 0.0000009 wt% or more, 0.0000009 wt% or more, 0.000001 wt% or more, 0.000002 wt% or more, 0.000004 wt% or more, 0.000006 wt% or more, 0.000008 wt. At least 0.00003% by weight, at least 0.00005% by weight, at least 0.00007% by weight, at least 0.00009% by weight, at least 0.00009% by weight, at least 0.0001% by weight, at least 0.0003% by weight, at least 0.0005% by weight, at least 0.0007% by weight, % Or more, 0.01 wt% or more, 0.1 wt% or more, 1 wt% or more, 3 wt% or more, 5 wt% or more, 7 wt% or more, 9 wt% or more, 10 wt% or more, 13 wt% or more, Or more, 17 wt% or more, 19 wt% or more, 21 wt% or more, 23 wt% or more, 25 wt% or more, 27 wt% or more, 29 wt% or more, 30 wt% or more, 31 wt% 32 weight% or less, 31 weight% or less, 30 weight% or less, 29 weight% or less, 28 weight% or less, 26 weight% or less, 24 weight % Or less, 22 wt% or less, 20 wt% or less, 18 wt% or less, 16 wt% or less, 14 wt% or less, 12 wt% or less, 10 wt% or less, 9 wt% or less, 8 wt% % Or less, 4 wt% or less, 2 wt% or less, 1 wt% or less, 0.1 wt% or less, 0.09 wt% or less, 0.04 wt% or less, 0.01 wt% or less, 0.006 wt% or less, 0.001 wt% 0.000003 wt.% Or less, 0.00003 wt.% Or less, 0.00001 wt.% Or less, 0.00001 wt.% Or less, 0.000009 wt.% Or less, 0.000007 wt.% Or less, 0.000005 wt. %, 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, or 0.00000009 wt% or less.

Another aspect of the invention includes the use of the composition of the present invention to enhance skin barrier.

In one aspect, the present invention provides a composition for enhancing skin barrier by regulating the expression level of a specific gene in skin cells damaged by a stimulus causing skin barrier weakness to a normal level.

In one aspect, the composition can be applied to keratinocytes.

Specifically, in the present invention, the genes in the skin cells to which the expression level is influenced by the stimuli that cause skin barrier weakness include S100A7 (NM_002963), IL-36G (NM_019618), and LCE3D (NM_032563). Since the expression levels of S100A7 (NM_002963), IL-36G (NM_019618) and LCE3D (NM_032563) are increased by stimulation that causes skin barrier weakness, the expression level of these genes is suppressed and regulated to a normal level .

In one aspect, the genes whose expression levels are increased by the stimuli causing skin barrier weakness used in the present invention are shown in [Table 1]. In the table, Name means the genebank accession ID of NCBI, Gene Symbol means the official gene symbol, and Gene title means the name of each gene.

Increase gene Name Gene
Symbol Gene title NM_002963 S100A7 S100 calcium binding protein A7 NM_019618 IL36G interleukin 36, gamma NM_032563 LCE3D late cornified envelope 3D

Analysis of the expression level of the gene or protein can be performed using a microarray, PCR, NGS (Nest Generation Sequencing), Western blot, northern blot, ELISA, radioimmunoassay, radioimmunoassay, tissue immuno staining, Can be analyzed using a variety of analytical methods known in the art.

In one aspect of the present invention, the composition may be a cosmetic composition, a pharmaceutical composition, or a health functional food composition.

Examples of the cosmetic composition include cosmetics such as various creams, lotion creams, lotions, skins, and the like, and cleansing, cleansing agents, soaps, and essences.

In one aspect, the cosmetic composition to which the composition containing the fermented tea extract of the present invention is added may take the form of a solution, an emulsion, a viscous mixture or the like.

That is, the cosmetic as one aspect of the present invention is not particularly limited in its formulation and may be, for example, an emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, Formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, rinse, body cleanser, soap, hair dye, spray and the like.

In the cosmetic composition of each formulation, the components other than the fermented tea extract may be mixed and selected without difficulty by those skilled in the art depending on the formulations of the other cosmetic preparations or the intended use.

The cosmetic composition according to one aspect of the present invention may further comprise a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.

In one aspect, the cosmetic composition of the present invention may contain, in addition to the above essential ingredients, other ingredients usually added to cosmetics, if necessary.

Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.

The components to be added in addition to these components are not limited thereto, and any of the above components can be compounded within a range that does not impair the objects and effects of the present invention.

In one aspect, the pharmaceutical compositions comprising the fermented tea extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.

The pharmaceutical composition containing the fermented tea extract may be formulated into tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays according to a conventional method, And can be formulated and used in any form suitable for pharmaceutical preparations.

In general, it is to be understood that the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of various relevant factors such as the severity of the symptoms, the route of administration selected, the age, sex, weight and health status of the subject. In general, the dosage of the active ingredient may be from 0.0001 mg / kg / day to 3000 mg / kg / day, for example from 10 mg / kg / day to 500 mg / kg / day.

In the health functional food composition as one aspect of the present invention, the health food is produced by using a raw material or a component (functional raw material) having a function useful for a nutrient or a human body which is likely to be deficient in a daily meal, Or to maintain or improve health through the activation of physiological functions. However, the present invention is not limited thereto. The health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and circles, but is not limited thereto and may be manufactured and processed in any form according to the law.

Specifically, the health beverage composition has no particular limitation on the other ingredients other than the above-mentioned compounds as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary beverages. Examples of natural carbohydrates are conventional sugars such as monosaccharide polysaccharides, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings other than those described above.

In general, it should be understood that the actual dosage of the active ingredient administered by the health functional food composition should be determined in light of various relevant factors such as the severity of the symptoms, the selected route of administration, the age, sex, weight and health status of the subject . In general, the dosage of the active ingredient may be from 0.0001 mg / kg / day to 1000 mg / kg / day, for example from 0.02 mg / kg / day to 6 mg / kg / day.

Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to examples. However, these examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.

[Example 1] Production of fermented tea

1-1 Fermentation Stage

The fermented tea was prepared by piled up dried green tea leaves. The fermented tea was naturally fermented by making a hot and humid environment so that the moisture content of green tea leaves could be 30-50%. The prepared green tea leaves were fermented at 45 ℃ for 6 weeks.

1-2 Ripening stage

The fermented tea fermented in the fermentation stage was placed in Jejun Onggi and fermented for 50 days.

[Example 2] Analysis of components of fermented tea

The fermented tea component prepared in Example 1 was analyzed via Thermo's Q Exact High Resolution LC-MS. As can be seen in the chromatogram of Figure 3, the cicinacid standard was detected at 0.65 min and theoretically had a value of m / z 191.05556 in negative ion mode. Peaks were detected in the negative ion mode TIC of the fermented tea when the ion extraction was performed in the molecular weight range of 191.05400 to 191.05650 at the same RT 0.65 min as the standard product. The peak exhibited an m / z value of 191.05505, which is the same as the m / z 191.05556 and the error ppm 2.6 in the theoretical m / z of the acetic acid, to the fourth decimal place. Therefore, the 0.65 minute peak in the raw material can be identified as a cicinic acid.

[Example 3] Preparation of fermented tea extract

The fermentation tea of Example 1 was extracted at room temperature using an extraction solvent in which purified water and ethanol were mixed at a ratio of 3: 7, that is, 70% ethanol as an extraction solvent. After extracting at room temperature, primary filtration was performed to remove the solid material contained in the extract. Then, the extract was concentrated to remove ethanol, and then it was separated and purified. After centrifugation, secondary filtration and drying, a fermented tea extract was obtained.

[Example 4] Preparation of skin barrier weakening stimulus source

The filter pack used a low volume air sampler (Sensidyne, Gillian, Low Volume Air Sampler, FL, USA) for the collection of fine dusts that caused skin barrier weakness. The filter pack replaced filter and denuder at around 10:00 am Samples were taken for about 24 hours. For 28 days, fine dust was collected daily from the windy area of Seoul (Gyeonggi-do, Korea), and the measurement time was measured by turning on the timer while turning on the vacuum pump and turning off the timer Time was recorded. The flow rate was measured with a flow meter (Model 4143, TSI Inc.) at the start of the measurement at a flow rate of 16.7 L / min, and the flow rate was measured again at the end of the measurement. The Teflon filter in the filter pack weighed before and after sampling. Before measuring the weight of the Teflon filter, the sample was weighed into a desiccator (NIKKO, Japan) with a relative humidity of 40% for 24 hours and then weighed twice on an electronic balance (DVG215CD, Ohaus) . After the sample was collected, the sample was weighed in a desiccator for 24 hours before measuring the weight, and then the weight was measured twice, and the mass concentration was calculated by comparing with the weight measured before the sampling. The extraction of fine dust was carried out by wetting the Teflon filter with 1 mL of ethanol, placing the filter with 14 mL of DW, closing the lid with the filter surface of the filter touching the water surface, and ultrasonically applying the filter with the ultrasonic cleaner for 30 minutes. In order to minimize the error caused by moisture in the filtration step, the water content of the filter was completely removed for 48 hours in a decicator, and then the weight of the filter was measured using a super-precision scale system (Mettler Toledo Company) Weighed and weighed before and after filter extraction.

[Example 5] (normal human) Culturing of keratinocyte cell line

Human normal epidermal keratinocytes were purchased from Lonza, Inc. (Walkersville, Maryland, USA), subcultured and cultured in a CO 2 incubator at 37 ° C under 5% CO 2 Lt; / RTI > The cell culture was in accordance with Lonza's guidelines. (KGM-2 Bullet kit, CC-4152) (ingredient: BPE (bovine pituitary extract)), human epidermal growths (KBM- (Gentamycin Suflate + Amphofericin-B: GA), human epidermal growth factor (hEGF), insulin, Hydrocortisone, Transferrin, Epinephrine and gentamycin sulfate (KGM-2 Bullet Kit, CC-3107) was added to the reaction mixture.

[Example 6] (Normal human) Treatment of fine dust and cytotoxicity measurement on keratinocyte cell line

MTT experiments were carried out using keratinocyte lines (normal human) by the method of Mossman et al. (J. Immunol. Methods, 65, 55-63, 1983) in order to confirm cytotoxicity through fine dusting.

Specifically, using a 24-well plate, and the cell culture conditions in Example 4 were collected to prepare a dispersion of fine particles by dispersing the fine particles in the obtained diameter 2.5㎛ in purified water, and then, a 2.5 × 10 ⁵ Example 5 Cells cultured under the conditions of the number of well cells were treated with the fine dust dispersion and cultured for 24 hours. Then, 5 mg / ml of MTT (3-4,5-dimethylthiazol-2,5-diphenyltetra zolium bromide) Lt; 0 > C for 3 hours. The medium was then removed and the formazan crystal formed was dissolved in 500 占 퐇 of DMSO. The lysate was transferred to a 96-well plate and aliquoted and the OD value measured at 540 nm absorbance. The measurement results are shown in Fig.

As shown in FIG. 1, the concentration (IC20) showing an 80% survival rate with respect to cytotoxicity by a dispersion in which fine particles of 2.5 micrometer or less were dispersed in the cell line was 12.5 g / Ml.

[Example 7] Confirmation of cellular genetic changes of fine dusts through next generation sequencing

For RNA-base sequence data processing and analysis, reference was made to the general analysis step developed by Trapnell et al. (2012). We confirmed the RNA-seq data quality using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and used FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) , Thereby removing the base and the adder sequences with low accuracy. Afterwards, alignment was performed using Tophat (Trapnell et al., 2009) and human genome (hg19), and the amount of data for each sample was confirmed using EVER-seq renamed RSeQC (Wang et al., 2012 ). In addition, the level of expression of transcripts was quantified using Cufflinks, and transcription levels were compared between the fine dust dispersion treated and normal samples (Trapnell et al., 2010). A stringent cutoff of ≥2.0 fold-change was applied to the FDR adjusted p-value <0.05 to determine the gene that showed significant expression differences in the treatment of the dispersion of fine dust with a diameter of 2.5 μm. The measurement results are shown in the following [Table 2] and [Figure 2a] to [Figure 2c].

Increase gene Name Gene
Symbol Drainage variation NM_019618 IL36G 7.1 NM_002963 S100A7 23.8 NM_032563 LCE3D 12.0

[Example 8] Real-time RT-PCR quantification

Human microkeratome cells cultured in Example 5 were cultured in the amount of 12.5 占 퐇 in 1 ml of the cell culture medium and microspheres having a diameter of 2.5 占 퐉 extracted in Example 4 were treated with applied primers TaqMan® Primers) to determine the relative mRNA expression levels. The fermented tea extract used in Example 3 was used.

Increase gene Name Gene
Symbol TaqMan® primer NM_019618 IL36G Hs00219742_m1 NM_002963 S100A7 Hs00161488_m1 NM_032563 LCE3D Hs00754375_s1

After the fermented tea extract was treated at a concentration of 20 ppm for 24 hours, the culture solution was removed, and the cells were washed with 2 ml of phosphate buffered saline (PBS). Then, the triazol reagent (Trizol reagent, Invitrogen, Carlsbad, CA, USA). The separated RNA was further purified with an RNA kit (QIAGEN RNeasykt, QIAGEN, Valencia, Calif.) From Agilent Technologies, Inc., Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, ) Was used to confirm the quality of the RNA. CDNA was synthesized from the above RNA using a reverse transcription kit (Invitrogen, Carlsbad, Calif.) Of Invitrogen, and the cDNA was synthesized using the primers in the real time reverse transcription polymerase chain reaction (Q -RT-PCR: real-time reverse transcription polymerase chain reaction). The change in gene expression pattern was evaluated by real-time PCR using a TaqMan gene expression assay kit (Applied Biosystems, Foster City, Calif.) Of Applied Biosystems. As shown in Fig. 2C. Both Q-RT-PCR and real-time PCR were performed according to the standard protocols distributed by Life Technologies. Specifically, the Q-RT-PCR was performed at 95 ° C for 20 seconds, followed by 95 ° C for 3 seconds and 60 ° C for 30 seconds For 40 cycles.

As shown in FIGS. 2A to 2C, there is a gene whose expression level is increased or decreased in skin cells stimulated by fine dusts. The interleukin-1 beta (IL-1B) The expression level of interleukin-36 gamma (IL-36G), S100 calcium binding protein A7 (S100A7), late keratin hyaluronan 3D (LCE3D), prostaglandin-endo peroxidase 2 (PTGS2) and xanthine dehydrogenase Respectively.

Accordingly, the fermented tea extract effectively protects skin cells from skin cell damage caused by stimulation that causes skin barrier weakness, suppresses or prevents the change in the expression level of the specific gene described above by stimulation that causes skin barrier weakness, Lt; RTI ID = 0.0 &gt; of &lt; / RTI &gt;

Hereinafter, formulation examples of the composition according to the present invention will be described. However, the cosmetic composition, the pharmaceutical composition and the health functional food composition can be applied to various formulations, and the present invention is not limited thereto .

[Formulation Example 1] Tablets

100 mg of the fermented tea extract according to the present invention, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate were mixed, and tablets were prepared by tableting according to a conventional preparation method of tablets.

Compounding ingredient Content (mg) Fermented tea extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2

[Formulation Example 2]

100 mg of the fermented tea extract according to the present invention, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

Compounding ingredient Content (mg) Fermented tea extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2

[Formulation Example 3]

50 mg of fermented tea extract according to the present invention, 250 mg of anhydrous crystalline glucose and 550 mg of starch were mixed and granulated into granules using a fluidized bed granulator, and filled in a capsule.

Compounding ingredient Content (mg) Fermented tea extract 50 Anhydrous crystalline glucose 250 Starch 550

[Formulation Example 4] Soap

Compounding ingredient content(%) Fermented tea extract 5.00 maintain Suitable amount Sodium hydroxide Suitable amount Sodium chloride Suitable amount Spices Suitable amount Purified water Balance

[Formulation Example 5] Lotion

Compounding ingredient content(%) Fermented tea extract 5.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Water soluble collagen (1% aqueous solution) 1.00 Sodium citrate 0.10 Citric acid 0.05 Licorice extract 0.20 1,3-butylene glycol 3.00 Purified water Balance

[Formulation Example 6] Cream

Compounding ingredient content(%) Fermented tea extract 3.00 Polyethylene glycol monostearate 2.00 Self emulsifying monostearic acid glycerin 5.00 Cetyl alcohol 4.00 Squalene 6.00 Tri-2-ethylhexanoic acid glyceryl 6.00 Sphingoglycolipids 1.00 1,3-butylene glycol 7.00 Purified water Balance

[Formulation Example 7] ointment

Compounding ingredient content(%) Fermented tea extract 5.00 Polyvinyl alcohol 13.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Lauroylhydroxyproline 1.00 Water soluble collagen (1% aqueous solution) 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water Balance

 [Formulation Example 8] Preparation of serum

Compounding ingredient content(%) Fermented tea extract 3.00 Hydroxyethylene cellulose (2% aqueous solution) 12.00 Xanthan gum (2% aqueous solution) 2.00 1,3-butylene glycol 6.00 Concentrated glycerin 4.00 Sodium hyaluronate (1% aqueous solution) 2.00 Purified water Balance

[Formulation Example 9] Health food

Compounding ingredient content Fermented tea extract 2 mg Vitamin A acetate 70 μg Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 μg Vitamin C 10 mg Biotin 10 μg Nicotinic acid amide 1.7 mg Folic acid 50 μg Calcium pantothenate 0.5 mg Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium monophosphate 15 mg Dicalcium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg

[Formulation Example 10] Health drinks

Compounding ingredient content Fermented tea extract 50 mg Citric acid 1000 mg oligosaccharide 100 g Taurine 1g Purified water Balance

Claims (10)

A composition for enhancing skin barrier comprising an extract of fermented tea as an active ingredient. The method according to claim 1,
Wherein the fermentation tea is naturally fermented with tea leaves in which an internal enzyme is inactivated. The method according to claim 1,
Wherein the fermented tea extract is included in an amount of 0.000001 to 30% by weight based on the total weight of the composition. The method according to claim 1,
Wherein the fermented tea extract is selected from the group consisting of water, at least one selected from the group consisting of C ₁ -C ₆ anhydrous or lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane &Lt; / RTI &gt; is extracted with a solvent. The method according to claim 1,
Wherein said composition inhibits expression of at least one selected from the group consisting of IL-36G (NM_019618), S100A7 (NM_002963) and LCE3D (NM_032563). 6. The method of claim 5,
Wherein the composition is applied to keratinocytes. The method according to claim 1,
Wherein the fermented tea extract is administered at a dose of 10 to 500 mg / kg / day. The method according to claim 1,
Wherein the composition is a cosmetic composition. The method according to claim 1,
Wherein the composition is a pharmaceutical composition. The method according to claim 1,
Wherein the composition is a health functional food composition.

Images